RBC Capital analyst Sean Dodge maintained a Hold rating on Catalent (CTLT – Research Report) yesterday and set a price target of $63.50. The company’s shares closed yesterday at $56.20.
Dodge covers the Healthcare sector, focusing on stocks such as R1 RCM, Sotera Health, and Evolent Health. According to TipRanks, Dodge has an average return of -7.1% and a 38.21% success rate on recommended stocks.
Catalent has an analyst consensus of Hold, with a price target consensus of $59.38.
The company has a one-year high of $60.20 and a one-year low of $31.45. Currently, Catalent has an average volume of 2.07M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalent (CTLT) Company Description:
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.
